$BRKR
BRUKER CORP

2023 Q2 Form 10-Q Financial Statement

#000095017023020404 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $681.9M $685.3M $595.0M
YoY Change 15.89% 15.18% 7.27%
Cost Of Revenue $341.4M $325.6M $288.7M
YoY Change 17.64% 12.78% 4.6%
Gross Profit $340.5M $359.7M $306.3M
YoY Change 14.19% 17.43% 9.9%
Gross Profit Margin 49.93% 52.49% 51.48%
Selling, General & Admin $177.9M $162.7M $145.7M
YoY Change 16.89% 11.67% 10.55%
% of Gross Profit 52.25% 45.23% 47.57%
Research & Development $71.00M $69.00M $56.60M
YoY Change 19.13% 21.91% 3.28%
% of Gross Profit 20.85% 19.18% 18.48%
Depreciation & Amortization $25.90M $25.10M $21.70M
YoY Change 19.91% 15.67% -2.69%
% of Gross Profit 7.61% 6.98% 7.08%
Operating Expenses $254.3M $237.0M $209.8M
YoY Change 13.37% 12.96% 10.65%
Operating Profit $86.20M $122.7M $96.50M
YoY Change 16.64% 27.15% 8.31%
Interest Expense -$8.700M $4.200M -$2.500M
YoY Change 102.33% -268.0% -34.21%
% of Operating Profit -10.09% 3.42% -2.59%
Other Income/Expense, Net -$8.700M -$16.10M -$2.500M
YoY Change 102.33% 544.0% -34.21%
Pretax Income $77.50M $106.6M $94.00M
YoY Change 11.35% 13.4% 10.2%
Income Tax $19.90M $29.90M $31.90M
% Of Pretax Income 25.68% 28.05% 33.94%
Net Earnings $57.10M $76.50M $61.60M
YoY Change 15.35% 24.19% 8.64%
Net Earnings / Revenue 8.37% 11.16% 10.35%
Basic Earnings Per Share $0.39 $0.52 $0.41
Diluted Earnings Per Share $0.39 $0.52 $0.41
COMMON SHARES
Basic Shares Outstanding 146.7M 146.7M 150.4
Diluted Shares Outstanding 147.7 147.6 151.4

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $574.8M $597.9M $916.1M
YoY Change -20.5% -34.73% 22.67%
Cash & Equivalents $574.8M $597.9M $816.1M
Short-Term Investments $100.0M
Other Short-Term Assets $243.1M $204.6M $181.0M
YoY Change 19.81% 13.04% 4.81%
Inventory $914.6M $858.8M $739.9M
Prepaid Expenses $36.40M
Receivables $450.8M $471.7M $413.8M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.183B $2.133B $2.251B
YoY Change 4.59% -5.23% 15.65%
LONG-TERM ASSETS
Property, Plant & Equipment $522.7M $510.9M $403.8M
YoY Change 32.33% 26.52% 5.13%
Goodwill $557.9M $527.3M $384.3M
YoY Change 40.81% 37.21%
Intangibles $300.4M $298.5M $227.5M
YoY Change 28.65% 31.21%
Long-Term Investments
YoY Change
Other Assets $292.7M $294.2M $284.3M
YoY Change 7.37% 3.48% 59.81%
Total Long-Term Assets $1.674B $1.631B $1.300B
YoY Change 29.01% 25.46% 19.4%
TOTAL ASSETS
Total Short-Term Assets $2.183B $2.133B $2.251B
Total Long-Term Assets $1.674B $1.631B $1.300B
Total Assets $3.857B $3.764B $3.551B
YoY Change 13.95% 6.0% 17.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $188.8M $196.2M $161.2M
YoY Change 21.89% 21.71% 5.84%
Accrued Expenses
YoY Change
Deferred Revenue $214.7M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $120.9M $120.1M $11.00M
YoY Change 763.57% 991.82% -89.85%
Total Short-Term Liabilities $1.051B $1.049B $880.5M
YoY Change 28.41% 19.08% -6.68%
LONG-TERM LIABILITIES
Long-Term Debt $1.123B $1.109B $1.205B
YoY Change -4.14% -8.0% 68.4%
Other Long-Term Liabilities $421.0M $395.6M $426.7M
YoY Change 4.03% -7.29% 8.33%
Total Long-Term Liabilities $1.544B $1.505B $1.632B
YoY Change -2.04% -7.81% 47.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.051B $1.049B $880.5M
Total Long-Term Liabilities $1.544B $1.505B $1.632B
Total Liabilities $2.606B $2.553B $2.513B
YoY Change 8.86% 1.61% 21.55%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.107B $1.107B $925.9M
YoY Change 12.27% 19.58%
Treasury Stock Shares $28.68M $25.75M
Shareholders Equity $1.251B $1.180B $1.017B
YoY Change
Total Liabilities & Shareholders Equity $3.857B $3.764B $3.551B
YoY Change 13.95% 6.0% 17.0%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $57.10M $76.50M $61.60M
YoY Change 15.35% 24.19% 8.64%
Depreciation, Depletion And Amortization $25.90M $25.10M $21.70M
YoY Change 19.91% 15.67% -2.69%
Cash From Operating Activities $13.00M $87.50M $77.80M
YoY Change -129.28% 12.47% -20.61%
INVESTING ACTIVITIES
Capital Expenditures $23.50M $25.00M $19.00M
YoY Change -231.28% 31.58% -23.08%
Acquisitions $88.10M $83.80M
YoY Change 5.13% 1995.0%
Other Investing Activities -$2.500M -$83.20M -$82.80M
YoY Change -103.33% 0.48% -11928.57%
Cash From Investing Activities -$26.00M -$108.2M -$101.8M
YoY Change -145.53% 6.29% 324.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $102.5M
YoY Change 225.4%
Debt Paid & Issued, Net $2.100M
YoY Change
Cash From Financing Activities -10.30M -30.70M -217.4M
YoY Change -87.09% -85.88% 470.6%
NET CHANGE
Cash From Operating Activities 13.00M 87.50M 77.80M
Cash From Investing Activities -26.00M -108.2M -101.8M
Cash From Financing Activities -10.30M -30.70M -217.4M
Net Change In Cash -23.30M -47.30M -252.1M
YoY Change -65.28% -81.24% -1791.95%
FREE CASH FLOW
Cash From Operating Activities $13.00M $87.50M $77.80M
Capital Expenditures $23.50M $25.00M $19.00M
Free Cash Flow -$10.50M $62.50M $58.80M
YoY Change -60.38% 6.29% -19.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001109354
CY2023Q1 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
8200000
CY2023Q1 dei Entity File Number
EntityFileNumber
000-30833
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BRUKER CORPORATION
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3110160
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
40 Manning Road
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Billerica
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01821
CY2023Q1 dei City Area Code
CityAreaCode
978
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
663-3660
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
BRKR
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
146727377
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
597900000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
645500000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
471700000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
472700000
CY2023Q1 us-gaap Inventory Net
InventoryNet
858800000
CY2022Q4 us-gaap Inventory Net
InventoryNet
800100000
CY2023Q1 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
0
CY2022Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
1400000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
204600000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
193500000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
2133000000.0
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2113200000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
510900000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
487000000.0
CY2023Q1 us-gaap Goodwill
Goodwill
527300000
CY2022Q4 us-gaap Goodwill
Goodwill
457600000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
298500000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
270900000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
294200000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
283100000
CY2023Q1 us-gaap Assets
Assets
3763900000
CY2022Q4 us-gaap Assets
Assets
3611800000
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
120100000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
18700000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
196200000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
178400000
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
397800000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
370200000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
334400000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
347000000.0
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1048500000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
914300000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1109000000.0
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1200500000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
395600000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
365200000
CY2023Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
12000000.0
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
6100000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
175443006
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
175389586
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
146761246
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
147023144
CY2023Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2023Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
28681760
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
28366442
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
1107200000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1085000000.0
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
29600000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14800000
CY2023Q1 brkr Other Shareholders Equity
OtherShareholdersEquity
2256200000
CY2022Q4 brkr Other Shareholders Equity
OtherShareholdersEquity
2182300000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1180300000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1113800000
CY2023Q1 us-gaap Minority Interest
MinorityInterest
18500000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
11900000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1198800000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1125700000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3763900000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3611800000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1125700000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
685300000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
595000000.0
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
325600000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
288700000
CY2023Q1 us-gaap Gross Profit
GrossProfit
359700000
CY2022Q1 us-gaap Gross Profit
GrossProfit
306300000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
162700000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
145700000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69000000.0
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56600000
CY2023Q1 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
5300000
CY2022Q1 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
7500000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
237000000.0
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
209800000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
122700000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
96500000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16100000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2500000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
106600000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
94000000.0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29900000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31900000
CY2023Q1 brkr Equity In Income Of Unconsolidated Investees Net Of Tax
EquityInIncomeOfUnconsolidatedInvesteesNetOfTax
700000
CY2022Q1 brkr Equity In Income Of Unconsolidated Investees Net Of Tax
EquityInIncomeOfUnconsolidatedInvesteesNetOfTax
0
CY2023Q1 us-gaap Profit Loss
ProfitLoss
77400000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
62100000
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
900000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
500000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
76500000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
61600000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.8
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150.4
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.6
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151.4
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
92600000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
53200000
CY2023Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1300000
CY2022Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
200000
CY2023Q1 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
0
CY2022Q1 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-200000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
91300000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53200000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
700000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-100000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4100000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
200000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
22300000
CY2023Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2023Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
5300000
CY2023Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
77500000
CY2023Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
15100000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1198800000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1084600000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3100000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3800000
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
105600000
CY2022Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7500000
CY2022Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
-62100000
CY2022Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-9200000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1031300000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
77400000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
62100000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25100000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21700000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6500000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8000000.0
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1200000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4000000.0
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
6900000
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2000000.0
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
9800000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
10700000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5000000.0
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2500000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8300000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2400000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
55000000.0
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
49000000.0
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13100000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-100000
CY2023Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-5800000
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
600000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
34800000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
45300000
CY2023Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
20200000
CY2022Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1800000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
87500000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
77800000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000000.0
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000000.0
CY2023Q1 us-gaap Other Inventory In Transit
OtherInventoryInTransit
38800000
CY2022Q4 us-gaap Other Inventory In Transit
OtherInventoryInTransit
41100000
CY2022Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
12000000.0
CY2023Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
88100000
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
83800000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10700000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12700000
CY2023Q1 us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-2400000
CY2022Q1 us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-300000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108200000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-101800000
CY2023Q1 us-gaap Proceeds From Repayments Of Other Debt
ProceedsFromRepaymentsOfOtherDebt
-2100000
CY2022Q1 us-gaap Proceeds From Repayments Of Other Debt
ProceedsFromRepaymentsOfOtherDebt
-400000
CY2023Q1 brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
0
CY2022Q1 brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
-105000000.0
CY2023Q1 brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-3800000
CY2022Q1 brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-800000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
700000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3100000
CY2023Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1000000.0
CY2022Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1200000
CY2023Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
7400000
CY2022Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
7500000
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
22400000
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
105600000
CY2023Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
5300000
CY2022Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-30700000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-217400000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4100000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-10700000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47300000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-252100000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
648700000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1071700000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
601400000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
819600000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3200000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3500000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3500000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3500000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy &amp; Supercon Technologies (BEST).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BSI BioSpin Segment designs, manufactures and distributes enabling life science tools based on magnetic resonance technology. BioSpin Segment’s revenues are generated by academic and government research customers, pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and other industrial companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection) Segment designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Customers of the BSI CALID Segment include academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit and for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BSI Nano Segment designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; spark optical emission spectroscopy systems; Chipcytometry products and services for targeted spatial proteomics, multi-omic services; and products and services for spatial genomics research. Customers of the BSI Nano Segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials research and life science research analysis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BEST reportable segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of March 31, 2023 and December 31, 2022, and for the three months ended March 31, 2023 and 2022, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, the financial information presented herein does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At March 31, 2023, the Company’s significant accounting policies, which are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, have not changed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common to its industry including, but not limited to, global economic conditions, including increasing inflation, uncertainties caused by recent banking industry volatility, rapid technological change, government and academic funding levels, geopolitical uncertainties, changes in commodity prices, spending patterns of its customers, protection of its intellectual property, availability of key raw materials and components and other supply chain challenges, compliance with existing and future regulation by government agencies and fluctuations in foreign currency exchange rates and interest rates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has experienced supply chain interruptions as a result of general global economic conditions, including inflation and the threat of a potential recession, a tighter labor market and other factors including natural events and disasters. Various factors, including increased demand for certain components and production delays, are contributing to shortages of certain components used in the Company’s products and increased difficulties in the Company’s ability to obtain a consistent supply of materials at stable pricing levels. Supply shortages and longer lead times for components used in the Company’s products, including limited source components, has resulted and may continue to cause disruptions to the Company’s production activities, which has had and may continue to have an adverse effect on the Company’s financial condition or result of operations. These factors have impacted and may continue to impact the timing of the Company’s revenue, and have also resulted, and may in the future result in a delay of revenue, and an increase in manufacturing costs, all of which have adversely impacted and may continue to adversely impact the Company’s operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, geopolitical tensions, such as Russia's incursion into and ongoing war in Ukraine, ongoing conflicts between the United States and China, tariff and trade policy changes, economic sanctions, and increasing potential of conflict involving countries in Asia that are critical to the Company's supply chain operations, such as Taiwan and China, have resulted in increasing global instability and create uncertainty for global commerce. In addition to experiencing adverse economic impacts resulting from economic sanctions on Russia, as well as the prospect of a reduction in natural gas exports from Russia and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, the Company has ceased its Russian operations. Sustained or worsening global economic conditions and increasing inflation and geopolitical tensions have increased the Company's cost of doing business, impacted the Company's supply chain operations, caused certain of the Company's customers to reduce or delay spending and further intensified pricing pressures. Combined with increased inflation, potential energy shortages in Europe where we have significant operations and overall higher energy and transportation costs, these factors have affected and may continue to affect the Company's financial condition and result of operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the global supply chain interruptions, higher energy costs and shortages, the global economy, including inflation and the threat of recession, and geopolitical instability will directly or indirectly impact future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee cost related amounts, will depend on future developments that are highly uncertain, including as a result of new developments concerning global supply chain and various global conflicts. The Company has made estimates of the impact of these disruptions within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue previously included in other current liabilities on the consolidated balance sheet is currently presented together with customer advances. The change in prior period was made to conform to the current period presentation.</span></p>
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
128200000
CY2023Q1 us-gaap Other Inventory Demo
OtherInventoryDemo
98000000.0
CY2022Q4 us-gaap Other Inventory Demo
OtherInventoryDemo
92300000
CY2023Q1 us-gaap Inventory Net
InventoryNet
858800000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
685300000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
595000000.0
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
685300000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
595000000.0
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
685300000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
595000000.0
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2383100000
CY2023Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
67100000
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
61300000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
510900000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
471700000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
150400000
CY2023Q1 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
26700000
CY2023Q1 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
6900000
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
317600000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
300900000
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
310100000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
278700000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
133100000
CY2022Q4 us-gaap Inventory Net
InventoryNet
800100000
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
CY2022Q4 us-gaap Goodwill
Goodwill
457600000
CY2023Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
65000000.0
CY2023Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
4700000
CY2023Q1 us-gaap Goodwill
Goodwill
527300000
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
610500000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
312000000.0
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
298500000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
570300000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
299400000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
270900000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10700000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9200000
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1600000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1700000
CY2023Q1 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1208700000
CY2022Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1205100000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
1229100000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
1219200000
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
120100000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
18700000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1109000000.0
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1200500000
CY2023Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
741900000
CY2023Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
142200000
CY2023Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
599700000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.6
CY2023Q1 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1505700000
CY2023Q1 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-3100000
CY2022Q4 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1412300000
CY2022Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
9600000
CY2023Q1 brkr Notional Amount Of Derivative Sale Contracts
NotionalAmountOfDerivativeSaleContracts
1400000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29900000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31900000
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.280
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.339
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
56000000.0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
54900000
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
4700000
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
4200000
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
500000
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
400000
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.050
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
76500000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
61600000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.8
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150.4
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.8
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1.0
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151.4
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2023Q1 us-gaap Information Technology And Data Processing
InformationTechnologyAndDataProcessing
500000
CY2022Q1 us-gaap Information Technology And Data Processing
InformationTechnologyAndDataProcessing
1000000.0
CY2023Q1 us-gaap Profit Loss
ProfitLoss
77400000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
62100000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25800000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-30500000
CY2023Q1 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
-10700000
CY2022Q1 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
21100000
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
100000
CY2022Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
500000
CY2023Q1 brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
92600000
CY2022Q1 brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
53200000
CY2023Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1300000
CY2022Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
200000
CY2023Q1 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
0
CY2022Q1 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-200000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
91300000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53200000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4300000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3800000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4300000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3800000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2800000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2022Q3 brkr Excise Tax On Stock Repurchases
ExciseTaxOnStockRepurchases
0.010
CY2023Q1 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
300000
CY2022Q1 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
300000
CY2023Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2900000
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5100000
CY2023Q1 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
1600000
CY2022Q1 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
1100000
CY2023Q1 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
5300000
CY2022Q1 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
7500000
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
500000
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
400000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
1800000
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
500000
CY2023Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
800000
CY2023Q1 us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
-400000
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
1100000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1400000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
400000
CY2023Q1 us-gaap Interest Expense
InterestExpense
4200000
CY2022Q1 us-gaap Interest Expense
InterestExpense
4100000
CY2023Q1 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
6900000
CY2022Q1 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3300000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-100000
CY2023Q1 us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
100000
CY2022Q1 us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
300000
CY2023Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-3000000.0
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1600000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16100000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2500000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
685300000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
595000000.0
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
122700000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
96500000
CY2023Q1 us-gaap Assets
Assets
3763900000
CY2022Q4 us-gaap Assets
Assets
3611800000

Files In Submission

Name View Source Status
brkr-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-020404-index-headers.html Edgar Link pending
0000950170-23-020404-index.html Edgar Link pending
0000950170-23-020404.txt Edgar Link pending
0000950170-23-020404-xbrl.zip Edgar Link pending
brkr-20230331.htm Edgar Link pending
brkr-20230331.xsd Edgar Link pending
brkr-20230331_def.xml Edgar Link unprocessable
brkr-20230331_cal.xml Edgar Link unprocessable
brkr-20230331_lab.xml Edgar Link unprocessable
brkr-20230331_htm.xml Edgar Link completed
brkr-ex31_1.htm Edgar Link pending
brkr-ex31_2.htm Edgar Link pending
brkr-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending